Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Zimmer Biomet Holdings    ZBH

ZIMMER BIOMET HOLDINGS

(ZBH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/14/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
160.4(c) 159.25(c) 160.02(c) 158.39(c) 157.39(c) Last
621 681 771 367 961 245 950 927 1 014 903 Volume
+1.05% -0.72% +0.48% -1.02% -0.63% Change
More quotes
Financials (USD)
Sales 2020 8 222 M
EBIT 2020 2 264 M
Net income 2020 1 176 M
Debt 2020 6 153 M
Yield 2020 0,66%
Sales 2021 8 489 M
EBIT 2021 2 398 M
Net income 2021 1 351 M
Debt 2021 4 745 M
Yield 2021 0,69%
P/E ratio 2020 28,8x
P/E ratio 2021 24,9x
EV / Sales2020 4,69x
EV / Sales2021 4,37x
Capitalization 32 373 M
More Financials
Company
Zimmer Biomet Holdings specializes in designing, manufacturing, and selling orthopedic and dental reconstruction implants, spinal implants, and traumatology products. Net sales break down by family of products as follows: - reconstruction implants (59.4%): knees replacement (59.2% of net sales),... 
More about the company
Surperformance© ratings of Zimmer Biomet Holdings
Trading Rating : Investor Rating :
More Ratings
Latest news on ZIMMER BIOMET HOLDINGS
02/21ZIMMER BIOMET : Management's Discussion and Analysis of Financial Condition and ..
AQ
02/05BACTIGUARD PUBL : Year-end report 2019 Bactiguard Holding AB
AQ
02/04ZIMMER BIOMET : Description Reconciliation of Debt to Net Debt and Net Debt Leve..
PU
02/04ZIMMER BIOMET : Description Non-GAAP Financial Guidance
PU
02/04ZIMMER BIOMET : Description Reconciliation of Effective Tax Rate to Adjusted Eff..
PU
02/04ZIMMER BIOMET : Description Reconciliation of Operating Profit & Margin to Adjus..
PU
02/04ZIMMER BIOMET : Description Reconciliation of Gross Profit & Margin to Adjusted ..
PU
02/04ZIMMER BIOMET : Description Reconciliation of Debt to Net Debt
PU
02/04ZIMMER BIOMET : Description Reconciliation of Cash Flow from Operating Activitie..
PU
02/04ZIMMER BIOMET : Swings to Profit in 4Q; Positive Growth Outlook Ahead
DJ
02/04ZIMMER BIOMET HOLDINGS, INC. : Results of Operations and Financial Condition (fo..
AQ
02/04ZIMMER : 4Q Earnings Snapshot
AQ
02/04ZIMMER BIOMET : Announces Fourth Quarter and Full-Year 2019 Financial Results
PR
02/04ZIMMER BIOMET HOLDINGS : Annual results
CO
01/30ZIMMER BIOMET HOLDINGS : annual earnings release
More news
News in other languages on ZIMMER BIOMET HOLDINGS
01/30ZIMMER BIOMET HOLDINGS : publication des résultats annuels
01/30ZIMMER BIOMET HOLDINGS : Veröffentlichung des Jahresergebnisses
2019ZIMMER BIOMET HOLDINGS : Ex-dividend day for
2019ZIMMER BIOMET HOLDINGS : Ex-dividend day for
2019La centrale nucléaire américaine de Three Mile Island arrêtée définitivement
More news
Analyst Recommendations on ZIMMER BIOMET HOLDINGS
More recommendations
Sector news : Medical Equipment, Supplies & Distribution - NEC
02/21Pharmaceutical companies develop system to better track counterfeit drugs
RE
02/20FISHER & PAYKEL HEALTHCARE : F&P Healthcare Raises Fiscal Year Earnings, Revenue..
DJ
02/20SMITH & NEPHEW : +Nephew forecasts sales growth after best year since 2010
RE
02/18MEDTRONIC : Raises 2020 Guidance, Sets 4Q Outlook
DJ
02/18MEDTRONIC : 3Q Profit, Sales Rise
DJ
More sector news : Medical Equipment, Supplies & Distribution - NEC
Chart ZIMMER BIOMET HOLDINGS
Duration : Period :
Zimmer Biomet Holdings Technical Analysis Chart | ZBH | US98956P1021 | MarketScreener
Technical analysis trends ZIMMER BIOMET HOLDINGS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 31
Average target price 172,14  $
Last Close Price 157,39  $
Spread / Highest target 20,7%
Spread / Average Target 9,37%
Spread / Lowest Target -20,6%
EPS Revisions
Managers
NameTitle
Bryan C. Hanson President, Chief Executive Officer & Director
Larry C. Glasscock Non-Executive Chairman
Kenneth R. Tripp Senior VP-Global Operations & Logistics
Suketu P. Upadhyay Executive VP, Chief Financial & Accounting Officer
David J. Kunz VP-Global Quality, Clinical & Regulatory Affairs
Sector and Competitors
1st jan.Capitalization (M$)
ZIMMER BIOMET HOLDINGS5.15%32 373
MEDTRONIC PLC0.36%151 884
BAXTER INTERNATIONAL INC.10.82%47 313
HOYA CORPORATION-0.10%34 270
DEXCOM, INC.33.15%26 677
TERUMO CORPORATION-1.33%25 411